Countdown to Humana (HUM) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Analysts project Humana (HUM) to report Q3 EPS of $2.91, a 30.1% year-over-year decrease, despite an anticipated 9.1% revenue increase to $31.98 billion. The consensus EPS estimate has been revised down by 2.3% over the past 30 days, a critical indicator for investor sentiment. Underlying metrics suggest a higher Benefits Expense Ratio of 90.9% and declines in key medical membership segments, notably Individual Medicare Advantage and Total Medicare, which could pressure future profitability.

Analysis

Humana (HUM) is projected to report Q3 EPS of $2.91, marking a significant 30.1% year-over-year decline, despite an anticipated 9.1% revenue growth to $31.98 billion. This earnings forecast reflects a 2.3% downward revision in the consensus EPS estimate over the last 30 days, signaling a deteriorating analyst outlook prior to the release.

Further analysis of underlying metrics reveals potential margin compression, with the Benefits Expense Ratio - Consolidated expected to rise to 90.9% from 89.9% in the prior year. While premium revenues are projected to increase by 8.6% to $30.35 billion, investment income is forecast to decline by 21% to $271.05 million, contributing to the EPS pressure.

Membership trends are mixed; while Medicare stand-alone PDP, State-based contracts, and Group Medicare Advantage show growth, significant declines are projected in Individual Medicare Advantage (from 5.66M to 5.21M), Total Medicare (from 8.52M to 8.23M), and Military services (from 5.98M to 4.80M). Despite these fundamental challenges and a "moderately negative" sentiment score of -0.4, HUM shares have outperformed the S&P 500 over the past month, rising 11.3% against the index's 2.1%.

Key Decisions for Investors

• Monitor EPS revisions and Benefits Expense Ratio: The 2.3% downward EPS revision and projected increase in the Benefits Expense Ratio to 90.9% suggest potential margin pressure, warranting close attention to actual reported figures and management commentary on cost control.
• Evaluate membership segment performance: While some membership categories show growth, the projected declines in Individual Medicare Advantage, Total Medicare, and Military services could indicate competitive pressures or strategic shifts that require further investigation into their impact on future revenue streams.
• Assess market reaction post-earnings: Despite the moderately negative sentiment surrounding estimates, Humana's recent stock outperformance suggests a potential disconnect or anticipation of positive surprises, making the market's reaction to the actual earnings report crucial for short-term positioning.